Merck CEO sees human trials for Covid-19 vaccine candidate 'fairly soon'

Coronavirus chronicle

Reuters
03 September, 2020, 09:10 pm
Last modified: 03 September, 2020, 09:15 pm
Merck this year bought Austrian vaccine maker Themis Bioscience to gain its vaccine project that relies on a measles vector, and is also collaborating with research nonprofit IAVI on a second vaccine hopeful that uses the same technology as Merck’s Ebola vaccine ERVEBO
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, US, July 12, 2018. REUTERS/Brendan McDermid

Merck aims to start human trials on one of its Covid-19 vaccine candidates "fairly soon," with a second vaccine candidate likely to begin trials later this year, Chief Executive Kenneth Frazier said on Thursday.

Merck this year bought Austrian vaccine maker Themis Bioscience to gain its vaccine project that relies on a measles vector, and is also collaborating with research nonprofit IAVI on a second vaccine hopeful that uses the same technology as Merck's Ebola vaccine ERVEBO.

"Both of those are going forward," Frazier said during a virtual briefing sponsored by drug industry group International Federation of Pharmaceuticals Manufacturers & Association. "We expect to be able to start larger-scale human trials in the measles-virus vaccine fairly soon, and we expect to be able to start those clinical trials for the (IAVI vaccine) later this year."

Related Topics

Merck

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.